Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Macrophage phagocytic receptors refer to an array of cell-surface molecules on macrophages that enable recognition and internalization of pathogens, apoptotic cells, and debris via phagocytosis. These include both opsonic (requiring coating of the target, such as Fc receptors for IgG and complement receptors) and non-opsonic (directly recognizing pathogen- or damage-associated molecular patterns) receptors. Major classes are: Toll-like receptors (e.g., TLR2, TLR4, TLR5), central to recognition of bacterial and viral components; Scavenger receptors (e.g., SR-A, MARCO), which bind a variety of polyanionic ligands; C-type lectin receptors (e.g., Dectin-1, Dectin-2, Mincle, MCL, DC-SIGN, Mannose receptor/CD206) important for fungal and glycan recognition; Complement receptors (e.g., CR3/Mac-1), which bind complement-opsonized targets; Fc receptors (e.g., FcγRI/CD64, FcγRII/CD32, FcγRIII/CD16), which bind antibody-opsonized targets. Engagement of these receptors initiates cytoskeletal rearrangement, phagosome formation, and downstream production of inflammatory or anti-inflammatory cytokines, linking innate pathogen clearance to adaptive immune activation. Individual receptor targeting has been explored in therapy and biomarker development, but “macrophage phagocytic receptors” as a whole is too vague and plural to serve as a specific targetable entity. As this is not a single receptor, specific drugs or biologicals may target individual receptors within this group, e.g., antibodies targeting CD206, CD14, or modulating TLRs. Mechanisms are highly receptor specific, e.g., blocking TLR signaling, enhancing phagocytosis through CD206 agonists, etc. Some individual receptors are used as biomarkers, e.g., CD206 for M2 macrophages. Safety issues are tied to targeting specific phagocytic receptors; global modulation of phagocytosis can cause immunodeficiency or excessive inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Macrophage phagocytic receptors.